MedTrace Logo

Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan

NCT04559581 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 425

Last updated 2026-02-06

Study results available
· View outcomes & findings →

Summary

The primary objective is to evaluate the incidence of adverse drug reactions (focus on hepatic function disorders) of Ofev Capsules under the real world setting in patients with Chronic fibrosing Interstitial Lung Diseases with a progressive phenotype (PF-ILD).

Conditions

  • Lung Diseases, Interstitial

Interventions

DRUG

Nintedanib

Ofev Capsules as prescribed by the treating physician

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-02
Primary Completion
2024-12-18
Completion
2025-01-22

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04559581 on ClinicalTrials.gov